CA125 Becomes a Target for Destruction of Ovarian Cancer by Phase I Drug

May 1, 2013 7:50 pm

By: Cory Bentley, PhD

Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more

Clinical Trials for Ovarian Cancer Patients: Why Now?

February 1, 2013 7:44 pm

By: Cory Bentley, PhD & Teresa Gallagher, PhD

Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more